SPONSOR
Peking University People's Hospital
Total Trials
17
Recruiting
17
Phases
Phase 1, Phase 2, Phase 2, Phase 3, Phase 2
Conditions studied: Acute Myeloid LeukemiaPrimary Angle-closure GlaucomaOsteoarthitisOsteoporosisHER2-negative Early Breast CancerAcute Myeloid Leukemia (AML)MLL RearrangementGastrointestinal Stromal Tumor of StomachSubmucosal Tumor of StomachMultiple Myeloma, Newly Diagnosed
Peking University People's Hospital is a clinical research sponsor with 17 registered studies on ClinicalTrials.gov, of which 17 are actively recruiting participants. Research covers conditions including Acute Myeloid Leukemia, Primary Angle-closure Glaucoma, Osteoarthitis, Osteoporosis.
The trial portfolio spans Phase 1, Phase 2, Phase 2, Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Peking University People's Hospital
How many clinical trials has Peking University People's Hospital sponsored?
ClinicalMetric currently tracks 17 clinical trials sponsored by Peking University People's Hospital, of which 17 are actively recruiting participants. These trials cover conditions including Acute Myeloid Leukemia, Primary Angle-closure Glaucoma, Osteoarthitis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Peking University People's Hospital research focus on?
Peking University People's Hospital clinical trials span Acute Myeloid Leukemia, Primary Angle-closure Glaucoma, Osteoarthitis, Osteoporosis, HER2-negative Early Breast Cancer, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 2, Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Peking University People's Hospital clinical trial?
To participate in a Peking University People's Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peking University People's Hospital trials with current recruitment status updated daily.
Clinical Trials by Peking University People's Hospital
NCT06301425
Recruiting
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Acute Myeloid Leukemia
NCT07517302
Recruiting
Kahook Dual Blade Goniotomy in Chronic Primary Angle-Closure Glaucoma
Primary Angle-closure Glaucoma
NCT07474571
Recruiting
Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging
Osteoarthitis
NCT04836156 Phase 1, Phase 2
Recruiting
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
HER2-negative Early Breast Cancer
NCT07537738
Recruiting
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML)
NCT06748690
Recruiting
MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
Gastrointestinal Stromal Tumor of Stomach
NCT06879379 Phase 2, Phase 3
Recruiting
KPD Consolidation After ASCT in NDMM Patients
Multiple Myeloma, Newly Diagnosed
NCT06714383 Phase 2
Recruiting
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Osteosarcoma
NCT06169449
Recruiting
Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment
Endometrium Cancer
NCT06880913 Phase 1, Phase 2
Recruiting
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT07101770
Recruiting
A Prediction Model in Pregnant Women With Aplastic Anemia
Aplastic Anemia
NCT06674382
Recruiting
Haplo-HSCT for Myelofibrosis
Myelofibrosis
NCT07586813 Phase 2
Recruiting
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Persistent Isolated Chemotherapy-Induced Thrombocytopenia
NCT06794008 Phase 2
Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Systemic Lupus Erythematosus
NCT06970912 Phase 2
Recruiting
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Hormone Receptor-Positive Breast Cancer
NCT06873100 Phase 1, Phase 2
Recruiting
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Relapsing Polychondritis
NCT06569095
Recruiting
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
Myelodysplastic Syndromes
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology